BioInvent International has carried out a primary issuance of shares of approximately SEK 300 million to international and Swedish institutional investors at a subscription price of SEK 46 per share.
BioInvent International is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with four programs in clinical development. The company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the company’s own clinical development pipeline or for additional licensing and partnering.
Kempen & Co and Pareto Securities acted as Joint Global Coordinators. Baker McKenzie acted as legal advisor to Kempen & Co and Pareto Securities with an international Capital Markets team consisting of Joakim Falkner, Johanna Flink and Sophie Gidlund in Stockholm as well as Adam Farlow and Charles Farnsworth in London
